New Directions
in New Therapies

Our Advantage

  • Novel device option in the treatment of Alzheimer's disease.
  • Minimally-invasive – no implantable devices or surgeries needed.
  • Reduced probability of complications and minimal side effects for patients versus implantable deep brain stimulation procedures.
  • Employs multiple therapeutic strategies – a more effective treatment option compared to the currently available symptomatic single agent drug therapies being explored.
  • Therapy can be performed on an outpatient basis - cheaper costs to patient and health system.
  • Less training will be required for the use of minimally-invasive SONS by medical professionals vs. invasive, implantable devices.
  • Therapy could possibly apply to other large neurodegenerative disease markets like Parkinson's, Depression, Epilepsy, Multiple Sclerosis, and Autism.

 *SONS is currently designated as an investigational device and limited by U.S. Federal law to investigational use